KR KRX

Samsung BioLogics Co., Ltd.

South Korean contract drug maker that changed the accounting treatment of an affiliate, inflating net profit by 4.5 trillion won prior to IPO.

CORPORATE IDENTIFIERS & DOSSIER
  • Entity Name: Samsung BioLogics Co., Ltd.
  • Country of Domicile: KR
  • Listing & Ticker: KRX (207940).
  • CIK / LEI Identifier: Unregistered.
  • Industry Classification: Pharmaceutical Preparations (SIC 2834).
  • Cumulative Overstatement: $3.8B across 1 enforcement episode(s).
  • Assessed Penalties: $7.0M.

PRIMARY ENFORCEMENT CASES INVOLVING SAMSUNG BIOLOGICS CO., LTD.

1 CASE DOSSIERS
Case Title Status Primary Scheme Overstatement Total Penalties Action Date
Samsung BioLogics: 4.5 Trillion Won Acquisition Accounting Inflation Adjudicated acquisition accounting abuse $3.8B $7.0M September 20, 2020

FORENSIC PROFILE: SAMSUNG BIOLOGICS: 4.5 TRILLION WON ACQUISITION ACCOUNTING INFLATION

FULL CASE DOSSIER →

Opportunistically changed valuation of joint venture affiliate Samsung Bioepis to fair value, manufacturing a 4.5T won net profit.

The company manipulated its accounting records by executing schemes under acquisition-accounting-abuse. Financial reports filed with market regulators contained material misstatements that distorted true financial condition.

Fraud Window: January 1, 2018 to December 31, 2020 • Primary Regulator: Financial Supervisory Service (South Korea) • Auditor: Samjong KPMG

Documented Accounting Irregularities & Regulatory Findings

  • ACQUISITION ACCOUNTING ABUSE: Opportunistically changed valuation of joint venture affiliate Samsung Bioepis to fair value, manufacturing a 4.5T won net profit.

Primary Public Dockets & Actions

  • [ENF-2018-samsung-biologics] Enforcement Action: Samsung BioLogics: 4.5 Trillion Won Acquisition Accounting Inflation (September 20, 2020): Opportunistically changed valuation of joint venture affiliate Samsung Bioepis to fair value, manufacturing a 4.5T won net profit. Official Record ↗